Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.
See "Use of Non-GAAP Financial Information". All comparisons are made versus the same period in 2023 unless otherwise stated. Bristol Myers Squibb posted third quarter revenues of $11.9 billion, an ...
The drugmaker said it now expects revenue to rise 5% for the year, compared with prior guidance for gains at the upper-end of the single-digit percentage range. Earnings are now expected to hit 75 ...